FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,276 letters match. Newest first.
-
DrugsUCSF Radiopharmaceutical Facility
FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.
High risk -
DrugsXiamen Kang Zhongyuan Biotechnology Co., Ltd.
FDA found filthy conditions and falsified records at Chinese drug maker Xiamen Kang Zhongyuan; cough drops recalled, imports blocked.
High risk -
DrugsRC Outsourcing, LLC
FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.
High risk -
DrugsThrive Health and Wellness, LLC dba Thrive Health Solutions
FDA warned Thrive Health and Wellness, a Colorado repackager, that sterile drugs were made in unsanitary conditions and sold without approval.
High risk -
DrugsApollo Care, LLC
FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.
High risk -
DrugsMedical Products Laboratories, Inc.
Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.
High risk -
DrugsChemco Corporation
FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.
High risk -
DrugsPurolea Cosmetics Lab
Purolea Cosmetics Lab drug products were adulterated by insanitary conditions and manufacturing failures, and two Dermveda products are unapproved new drugs.
High risk -
DrugsBeauty of Aztlan LLC
FDA warns Beauty of Aztlan it sells unapproved, misbranded injectable botulinum toxin drugs online to U.S. consumers.
High risk -
DrugsDry Springs Pharmacy
FDA warned Dry Springs Pharmacy that its website sells unapproved and misbranded opioids, benzodiazepines, and stimulants to U.S. consumers.
High risk -
DrugsOnline Rx Medz
FDA warns Online Rx Medz for selling unapproved, illegally labeled opioids, benzodiazepines, and stimulants online.
High risk -
DrugsRxgoodusa
FDA warned Rxgoodusa that its website sells unapproved, misbranded opioid and benzodiazepine drugs to U.S. consumers without prescriptions.
High risk -
DrugsPure Indulgence Aesthetics
Pure Indulgence Aesthetics, a medical spa, was cited for buying Botox from unauthorized sources and lacking product identifiers.
High risk -
DrugsLovega LLC dba Pink Pony Peptides
FDA warned Pink Pony Peptides that its GLP-2 TZ, GLP-3 RT and Bacteriostatic Water are unapproved new drugs sold online.
High risk -
DrugsGuangzhou Huli Technology Co., Ltd. dba Fantasy Face
FDA warned Guangzhou Huli Technology (dba Fantasy Face) for selling an unapproved GLP-1 weight loss drug online.
Medium -
DrugsGram Peptides
Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.
High risk -
DrugsPrime Sciences
Prime Sciences sells injectable peptide drugs and BAC water online without FDA approval, FDA says.
High risk -
DrugsFormPour
FDA warned FormPour over selling an unapproved new drug, SMGT-GLT-1 Nano Microneedle Patch, on eBay.
High risk -
DrugsMile High Compounds LLC
FDA warned Mile High Compounds that it sells unapproved injectable GLP-1-like drugs and BAC water online.
High risk -
DrugsPekCura Labs
FDA warned PekCura Labs that its GLP-1-S, GLP-2-T, GLP-3-R, and bacteriostatic water products are unapproved new drugs sold online.
High risk -
DrugsEhsan Sadri, M.D.
FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.
High risk -
DrugsMicrobiological Testing & Consulting, LLC
FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.
High risk -
DrugsYangzhou H&R Plastic Daily Chemical Co., Ltd.
Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.
High risk -
DrugsImmunityBio, Inc.
FDA says ImmunityBio's Anktiva TV ad and podcast falsely claim it can cure or prevent all cancers.
High risk -
DrugsPatcos Cosmetics Pvt. Ltd.
Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.
High risk -
DrugsOraLabs, Inc.
FDA warned OraLabs, an OTC drugmaker in Parker, Colorado, that it skipped microbial release testing and dismissed contamination findings.
High risk -
DrugsFlowchem Pharma Private Limited
FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.
High risk -
DrugsVedic Lifesciences Pvt. Ltd.
FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.
Medium -
DrugsCitra100mg
FDA warns Citra100mg it sells unapproved, misbranded tramadol opioids without prescriptions to U.S. consumers online.
High risk -
DrugsApothecary Pharma, LLC
FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.
High risk -
DrugsNovo Nordisk Inc.
FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.
High risk -
DrugsSimtra BioPharma Solutions
FDA found contamination risks in Simtra's sterile drug manufacturing in Germany, including microbial recoveries, failed isolator tests, and inadequate decontamination.
High risk -
DrugsTentamus India Private Limited
FDA warned India-based contract testing lab Tentamus over destroyed and backdated lab records and limited inspection access.
High risk -
DrugsFareva Morton Grove
FDA found microbial contamination risks and data integrity failures at Fareva Morton Grove's OTC drug manufacturing.
High risk -
DrugsNSE Products, Inc. DBA Nu Skin Enterprises, Inc.
FDA warns NSE Products (Nu Skin) over incomplete drug listing data for AP-24 products and 61 inactivated listings.
Low -
DrugsPremium Health Management Inc. dba Premium Health
FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.
Low -
DrugsZeuss LLC dba Zeuss
FDA warned telehealth seller Zeuss that its website misbrands compounded tirzepatide by implying Zeuss makes it and that it is FDA-approved.
Medium -
DrugsLean Rx, Inc. dba SkinnyRx
SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.
Low -
DrugsKare Solutions, LLC dba Zappy
FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.
Low -
DrugsStrut Health, LLC dba Strut
FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.
Low -
DrugsRefills Health, LLC dba Refills Health
FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.
Medium -
DrugsWeightless Medical LLC dba WeightCare
FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.
Low -
DrugsViv Health, Inc. dba VIV RX
FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsPeaks Curative, LLC dba Peaks
FDA warned Peaks Curative over false or misleading website claims for compounded (pharmacy-made) semaglutide, including implied FDA approval.
Low -
DrugsPharmaZee
FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.
Low -
DrugsGood Girl LLC dba GoodGirlRX
FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.
Medium -
DrugsIvim Services LLC dba Ivim
FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.
Low -
DrugsJoin Josie
FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.
Low -
DrugsKin Meds
FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.
Low -
DrugsLevity Inc. dba Levity
FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.
Low